您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Nifedipine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nifedipine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nifedipine图片
CAS NO:21829-25-4
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
500mg电议
1 g电议
5 g电议
10 g电议
50 g电议

产品名称
硝苯地平
BAY-a-1040
产品介绍
Nifedipine (BAY-a-1040) 是有效的钙离子通道 (calcium channel) 阻滞剂,常用于心肌功能不全的相关研究。
生物活性

Nifedipine (BAY-a-1040) is a potentcalcium channelblocker and drug of choice for cardiac insufficiencies.

体外研究
(In Vitro)

Nifedipine (BAY-a-1040) (100 μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells, and treatment of nifedipine (10 or 100 μM) plus FAC induces a significant reduction in cell viability, but there are no significant differences in viability between the control cells and the cells treated with 100 μM of FAC or 1 and 10 μM of nifedipine.Nifedipine (BAY-a-1040) (1, 10, or 100 μM) significantly increases iron level in WKPT-0293 Cl.2 cells. Nifedipine treatment also increases expression of TfR1, DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells. In addition, co-treatment with nifedipine (100 μM) and FAC (100 μM) increases TfR1, DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells[2]. Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations. The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine. The combination of nifedipine plus NS-1619 (Ca2+-activated K+[BKCa] channel opener) reduces the inhibitory effect of each drug[3]. Nifedipine (BAY-a-1040) (2 μM) significantly inhibitsP. capsicimycelial growth and sporulation. Nifedipine (BAY-a-1040)-induced inhibition of mycelial growth is calcium-dependent. Nifedipine (0.5 μM) increasesP. capsicisensitivity to H2O2in a calcium-dependent manner. Nifedipine inhibition ofP. capsicivirulence and expression of genes involved in pathogenicity[4].

体内研究
(In Vivo)

In Nifedipine (BAY-a-1040) (50 mg/kg)- and CsA-treated rats, the BL dimensions (BLi and BLk), MD dimensions (MDk) and vertical dimensions (VHi and VHk) are significantly increased (P< 0.05) at the end of the 4th week[1].

Clinical Trial
分子量

346.33

性状

Solid

Formula

C17H18N2O6

CAS 号

21829-25-4

中文名称

硝苯地平;心痛定;硝苯吡啶;硝苯啶

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL(288.74 mM;Need ultrasonic)

H2O : 1 mg/mL(2.89 mM;ultrasonic and warming and heat to 80℃)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.8874 mL14.4371 mL28.8742 mL
5 mM0.5775 mL2.8874 mL5.7748 mL
10 mM0.2887 mL1.4437 mL2.8874 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在本网站选购。